A hallmark of TDT's fundamental operating philosophy is
the creation of strategic technology and business alliances.
The objective of these alliances is to create the optimum
path to transform basic research technology into practically
applied diagnostic and therapeutic products, as rapidly and
safely as possible. Several discussions are underway, in addition
to those listed below.
Thomas Jefferson University
In 1994, TDT successfully negotiated a Research Funding Agreement
with Thomas Jefferson University. Under this agreement, TDT
has agreed to provide funding for sponsored research in colorectal
cancer receptors and certain other technologies in the field
of cancer and certain infectious diseases. Much of this work
is being conducted in the laboratories of Scott A. Waldman,
M.D., Ph.D., Samuel V. Hamilton Professor of Medicine, Division
of Clinical Pharmacology at Thomas Jefferson University.
Millennium Pharmaceuticals, Inc.
In November 2001, Millennium Pharmaceuticals, Inc. (Nasdaq:
MLNM) announced that TDT has granted Millennium a license
to TDT's intellectual property surrounding guanylyl cyclase
C (GC-C), a protein uniquely expressed on the cell surface
of colorectal tumors, and its related ST ligand for use in
colorectal cancer therapeutics. Millennium intends to utilize
these advanced components to develop both toxin and antibody-based
therapeutics directed against colorectal cancer. Due to the
utility demonstrated in preclinical work, Millennium believes
there is potential to create highly specific therapies that
may offer significantly improved efficacy and safety in the
fight against metastatic colorectal cancer.